CDA | Evidence Driven
CDA | Evidence Driven

Abraxane for Metastatic Pancreatic Cancer - Details

Details

Files
Generic Name:
Nab-paclitaxel
Project Status:
Complete
Therapeutic Area:
Metastatic Pancreatic Cancer
Manufacturer:
Celgene Inc.
Brand Name:
Abraxane
Project Line:
Reimbursement Review
Project Number:
PC0037-000
Performance Metric:
N/A — Predated performance metrics
Strength:
100 mg/vial
Tumour Type:
Gastrointestinal
Indications:
Metastatic Pancreatic Cancer
Funding Request:
For the first line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.
Pre Noc Submission:
Yes
Sponsor:
Celgene Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Clarification:
A delay in the receipt of marketing authorization (NOC) from Health Canada has impacted the review timeline.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Clarification:
A delay in the receipt of marketing authorization (NOC) from Health Canada has impacted the review timeline.
pERC Meeting:
Final Recommendation:

Files

Provincial Funding Summary View PDF
Nab-Paclitaxel (Abraxane) Metastatic Pancreatic Cancer - pERC Final Recommendation Final Recommendation September 23, 2014 View PDF
Nab-Paclitaxel (Abraxane) Metastatic Pancreatic Cancer - Final Clinical Guidance Report Guidance Reports September 23, 2014 View PDF
Nab-Paclitaxel (Abraxane) Metastatic Pancreatic Cancer - Final Economic Guidance Report Guidance Reports September 23, 2014 View PDF
Nab-Paclitaxel (Abraxane) Metastatic Pancreatic Cancer - pERC Initial Recommendation Initial Recommendation September 5, 2014 View PDF
Nab–Paclitaxel (Abraxane) Metastatic Pancreatic Cancer - PAG Feedback on Initial Recommendation Feedback September 23, 2014 View PDF
Nab–Paclitaxel (Abraxane) Metastatic Pancreatic Cancer - Manufacturer (Celgene Inc.) Feedback on Initial Recommendation Feedback September 23, 2014 View PDF
Nab–Paclitaxel (Abraxane) Metastatic Pancreatic Cancer - Patient Advocacy Group (PCC) COI Declarations Feedback September 23, 2014 View PDF
Nab-Paclitaxel (Abraxane) Metastatic Pancreatic Cancer - Patient Advocacy Group (Craig's Cause) COI Declarations Feedback September 23, 2014 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : October 8, 2014